Cell Engineering was the largest of Ginkgo Bioworks Holdings, Inc.’s 2 reported lines in fiscal 2025, at $398.24M — 78% of $510.47M.
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2025 |
|---|---|---|---|---|---|
| Service | $895.76M | $112.23M | |||
| Cell Engineering | $431.00M | $398.24M | |||
| Cell Engineering Revenue | — | — | |||
| Foundry Revenue | — | — | |||
| Product | $106.37M | — | |||
| Total | $1.43B | $510.47M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Ginkgo Bioworks Holdings, Inc. reported in this breakdown added up to $510.47M. The revenue lines reported changed from fiscal 2022, so the total is not directly comparable with the $1.43B reported that year. Cell Engineering was the largest revenue line, at $398.24M or 78.0% of the total, followed by Service ($112.23M, 22.0%).
Compared with fiscal 2022, the latest earlier year reported, every sizeable revenue line reported in both years shrank. Cell Engineering held up best, down 7.6% to $398.24M, while Service fell the most, down 87.5% to $112.23M. Because revenue lines were added or dropped between the two years, part of this reflects how Ginkgo Bioworks Holdings, Inc. regrouped its reporting.
The table also keeps 3 revenue lines that Ginkgo Bioworks Holdings, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers 5 fiscal years between 2019 and 2025, as reported in Ginkgo Bioworks Holdings, Inc.'s annual filings.
Cell Engineering was the largest of Ginkgo Bioworks Holdings, Inc.’s 2 reported lines in fiscal 2025, at $398.24M — 78% of $510.47M.
| Segment | FY 2021 | FY 2022 | FY 2025 |
|---|---|---|---|
| Biosecurity | $895.76M | $112.23M | |
| Cell Engineering | $431.00M | $398.24M | |
| Total | $1.33B | $510.47M |
In fiscal 2025, which ended December 31, 2025, the 2 segments Ginkgo Bioworks Holdings, Inc. reported in this breakdown added up to $510.47M. That was down 61.5% from $1.33B in fiscal 2022, the latest earlier year this breakdown was reported. Cell Engineering was the largest segment, at $398.24M or 78.0% of the total, followed by Biosecurity ($112.23M, 22.0%).
Compared with fiscal 2022, the latest earlier year reported, every sizeable segment reported in both years shrank. Cell Engineering held up best, down 7.6% to $398.24M, while Biosecurity fell the most, down 87.5% to $112.23M. Over fiscal 2022 to 2025, revenue across these segments went from $1.33B to $510.47M, a compound annual decline of 27.3%. Cell Engineering's share of the total rose from 32.5% to 78.0% over the same years.
This breakdown covers 3 fiscal years between 2021 and 2025, as reported in Ginkgo Bioworks Holdings, Inc.'s annual filings.
Arcaea was the largest of Ginkgo Bioworks Holdings, Inc.’s 6 reported lines in fiscal 2023, at $18.07M — 45% of $40.17M.
| Related and Nonrelated Parties | FY 2023 |
|---|---|
| Arcaea | $18.07M |
| Genomatica | $12.70M |
| Ayana Bio | $3.97M |
| Other Equity Investees | $2.12M |
| Verb Biotics | $1.75M |
| Allonnia | $1.57M |
| Total | $40.17M |
In fiscal 2023, which ended December 31, 2023, the 6 revenue lines Ginkgo Bioworks Holdings, Inc. reported in this breakdown added up to $40.17M. Arcaea was the largest revenue line, at $18.07M or 45.0% of the total, followed by Genomatica ($12.70M, 31.6%) and Ayana Bio ($3.97M, 9.9%). Together, the two largest revenue lines made up 76.6% of this total.
This breakdown covers every fiscal year from 2023 to 2023, as reported in Ginkgo Bioworks Holdings, Inc.'s annual filings.
Ginkgo Bioworks Holdings, Inc. (DNA) breaks its revenue down by revenue line and segment. In fiscal 2025, its largest revenue line was Cell Engineering, with $398.24M or 78.0% of the total, followed by Service at $112.23M (22.0%).
Cell Engineering was Ginkgo Bioworks Holdings, Inc.'s largest revenue line in fiscal 2025, with $398.24M in revenue, 78.0% of the $510.47M reported across its 2 revenue lines.
Cell Engineering was Ginkgo Bioworks Holdings, Inc.'s largest segment in fiscal 2025, with $398.24M in revenue, 78.0% of the $510.47M reported across its 2 segments.
Every figure is taken from Ginkgo Bioworks Holdings, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2019 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.